

REFERENCES

REFERENCES

1. **Ackerman Z:** Ascites in NS, incidence, patients, characteristics and complications. *J Clin Gastroenterol* 1996; 22(1): 314.
2. **Adkins B:** Early events in T cell maturation. *Ann Rev Immunology* 1987; 5: 325.
3. **Afrasiabi MA, Vaziri NP:** Thyroid function studies with NS. *Am Intern Med* 1999; 90: 335.
4. **Aksn N, Turker M:** CsA plus prednisone treatment of SSNS frequently relapsing in children. 1999; 41(2): 225 – 30.
5. **Anderson DC, York TL, Rose G:** Assessment of serum factor B, serum opsonins, granulocyte chemotaxis, and infection in NS of children. *J Infect Dis* 1979; 140: 1.
6. **Andrassy K, Ritz E, Bommer J:** Hypercoagulability in the nephrotic syndrome. *Klin Wochenschr* 1980; 58: 1025.
7. **Bagga A, Vasudev AS, Moudgil A, Srivastava RN.** Peripheral blood lymphocyte subsets in idiopathic nephrotic syndrome of childhood. *Indian J Med Res* 1996; 104 (1): 292 – 5.
8. **Barna BP, Makker B, Kallen R:** A lymphocytotoxic factors in plasma of patients with MCNS. *Clin Immunol Imuno Path* 1983; 27: 272.
9. **Barratt TM, Geary DF,** Therapy of glomerular disease: In Holliday MA, Barratt TM, eds. *Pediatric Nephrology* 2nd ed. Baltimore, Williams and Wilkins 1987; 528 – 43.

10. **Bergstein JM. Nephrotic syndrome. In: Beherman RE, Kliegman RM, Jenson Hb. Nelson text book of pediatrics. 16th ed. W.B Saunders Company Philadelphia, London, Toronto 2000: 1592 – 6.**
11. **Bierer BE, Steckman BP:** The biological roles of CD2, SD4 and CD8 in T cell activation. *Ann Rev Immunol* 1989; 7: 579 – 608.
12. **Bjorkman J, Saper MA:** Structure of the human class IMHC Ag, HLA-AZ. *Nature* 1987; 329: 506.
13. **Bock GH, Ongkingco JR, Patterson LT, Ruley J, Schroepfer LR, Nelson DL.** Serum and urine soluble interleukin-2 receptor in idiopathic nephrotic syndrome. *Pediatr Nephrol* 1993; 7 (5): 523 – 8.
14. **Bradehl J:** In what order should one introduce CP or chlorambucil or C5 or levamisole in a child with steroid-dependent frequently relapsing NS. *Pediatr Nephrol* 1993; 7(5): 514.
15. **Brown JH, Jarde T, Zky TS:** Three dimentional structure oB human class II MHC Ag HLA-DR. *Nature* 1993; 364: 33.
16. **Cameron JS:** Coagulation and thrombo-embolic complication in the NS. *Adv Nephrol* 1984; 13: 75.
17. **Carrie BJ, Salyer WR:** Minimal change nephropathy. *Am J Med* 1981; 70: 262.
18. **Celement LT:** Cellular interactivation in the human immune response In: Sliehman ER, ~~ad~~, *Immunologic disorders in infant and children. 4th ed, W.B Sounders Company, Philadelphia, London, Toronto 1996; 75 – 93.*

19. **Champman SJ, Cameron JS:** Treatment of mesangiocapillary glomerulonephritis with combined immunosuppressive and anticoagulant. *Arch Dis Child* 1980; 55: 446 – 51.
20. **Chesney RW.** The nephrotic syndrome. *Curr opin Pediatr* 1999; 11 (2): 158-61.
21. **Citak A, Emre S, Sairin A:** Haemostatic problems and thromboembolic complications in nephrotic children. *Pediatr Nephrol* 2000; 14(2): 138 – 42.
22. **Clive DM, Galvanek EG:** Mesangial immunoglobulin A deposits in MCNS. *Am J Nephrol* 1990; 10: 31.
23. **Cohen JJ:** Apoptosis and programmed cell death in immunity. *Ann Rev Immunol* 1992; 10: 207.
24. **Daniel V, Troutmann Y, Konrad M, Nayir A, Schnrer K.** T-lymphocyte populations, cytokines and other growth factors in serum and urine of children with idiopathic nephrotic syndrome. *Clin Nephrol* 1997; 47 (5): 289 – 97.
25. **Davis AE, Schneeberger EE:** Membranoproliferative glomerulonephritis and dense deposit disease in children. *Clin Nephrol* 1978; 9: 184 – 93.
26. **Dayol U, Dayol Ak, Shastry JC:** Use of levamisole in maintaining remission in SSNS in children. *Nephron* 1994; 66(4): 408 – 12.
27. **Dohi K, Morita H, Ogawa S, Hirayama T, Yamada H, Ishikawa H.** Production of interleukin-2 (IL-2) and responsiveness to IL-2 of peripheral blood lymphocytes in minimal change nephrotic syndrome.

- 28- **Dustin ML, Springer TA:** Role of lymphocyte adhesion receptor in transient interactions. *Ann Rev Immunol* 1991; 9: 27 – 66.
- 29- **El-Shafei AZ.** Evaluation of interleukin 1- β , interleukin 6, tumour necrosis factor- α and β_2 -microglobulin in children affected with primary nephrotic syndrome. Thesis, MD. Zagazig University, Banha Faculty of Medicine 2000; 131 – 45.
- 30- **Esparza AR, Sewell IK, Garella S:** Spectrum of acute renal failure in NS with minimal glomerular lesions 1981; 45: 510.
- 31- **Ferrara P, Ruggiero A, Puliano A:** Lipid metabolism and arteriosclerosis risk in renal diseases in pediatric age. *Minerva Pediatr* 1998; 50 (12): 513 – 8.
- 32- **Fodor P, Saitua T, Rodriguez E:** T cell dysfunction in MCNS of childhood. *Am J Dis Child* 1982; 136: 713.
- 33- **Fogo A, Hawkims EP:** Glomerular hypertrophy in MCNS predicts subsequent progression to focal glomerular sclerosis. *Kidney Int* 1990; 38: 115.
- 34- **Gahwalo. G, Abrol P, Tewar AD:** Hodgkin disease with NS. *Indian J Pediatr* 1994; 61 (4): 415-7.
- 35- **Garin GH:** Circulating mediators of proteinuria in MCNS. *Pediatr Nephrol* 2000, 14 (8-9): 872 – 8.
- 36- **Gelfand EW, Finkel TH:** The T-lymphocyte system. In Stiehm ER ed. *Immunologic disorder in infant and children*. 4th ed. W.B Saunders Company, Philadelphia, London, Toronto 1996; 14 – 35.

37. **Glangiacomo J, Cleary TC, Cole BR:** Serum immunoglobulin in the NS. *N Engl J Med* 1975; 293: 8.
38. **Glassock R J:** The nephrotic syndrome. *Hospital Practice* 1979; 14(11): 105 – 129.
39. **Goodman JW,** The Immune Response. In Stites PD, Stobo JD, Wells JV, eds. *Basic and Clinical Immunology* 8th ed. Norwalk, Appleton & Lange Norwalk, Connecticut 1994; 404.
40. **Gorensek MJ, Lebel MH, Nelson JD:** Peritonitis in children with NS. *Pediatrics* 1988; 81: 849.
41. **Grand J:** Mesangial function and glomerular sclerosis in rats with aminonucleoside nephrosis. *Kidney Int* 1985; 27: 405.
42. **Gregory MJ, Smoyer WE, Sedman A:** Long term C5 therapy for pediatric NS: A clinical and histologic analysis. *J Am Soc Nephrol* 1996; 7(4): 543 – 9.
43. **Grupe WE:** Management of primary NS. In: Postle Waite RJ, ed. *Clinical Pediatric Nephrology*, Bristol: Wright 1986; 175 – 95.
44. **Gutierre Z, Romas JC, Pezzi L:** IL-2 dependent autocrine proliferation in T cell development. *Nature* 1989; 342: 82 – 85.
45. **Hayer PF, Brodehl T, Ehrich JH:** Practical aspects in the use of cyclosporin in pediatric nephrology. *Pediatr Nephrol* 1991; 5: 636 – 8.
46. **Hinoshita F, Noma T, Tomrvea S, Shugai T, Yata J.** Decreased production and responsiveness of interleukin-2 in lymphocytes of patients with nephrotic syndrome. *Nephron* 1990; 54 (2): 122 – 6.

47. **Hoeffner A, Abbel M:** Oligotyping for HLA DQA-DQB and DPB in INS. *Pediatr Nephrol* 1997; 11 (3) : 291 –5.
48. **Hsieh CS, Heinberger AB:** Differential regulation of T helper phenotype development by IL-4 and 10 in α , B cell receptor transgenic system. *Proc Natl Acad Sci USA* 1992; 89: 6065.
49. **Hulton SA, Shah V, Byrne MR, Morgan G, Barratt TM, Dillon MJ.** Lymphocyte subpopulations, interleukin-2 and interleukin-2 receptor expression in childhood nephrotic syndrome. *Pediatr Nephrol* 1994; 8(2): 135 – 9.
50. **Imbasciati E, Ponticelli C, Case N:** Acute renal failure in INS. *Nephron* 1981; 28: 186.
51. **International study of kidney Disease in children:** NS in children: Prediction of histopathology from clinical and laboratory characteristic at time of diagnosis. *Kidney Int* 1987; 13: 159.
52. **International study of kidney disease in children:** Primary NS in children: Clinical significance of histopathology, pathologic variants of MCNS and diffuse mesangial hypercellularity. *Kidney Int* 1981; 20: 765.
53. **Janeway CA, Jones B:** A specificity and function of Tcs blaring and receptors. *Immunol Today* 1988; 9: 73.
54. **Janeway CA, Travers P, Walport M, Capra JD. Basic Concepts in Immunology.** In: **Janeway CA, Travers P, Walport M eds.** *Immunobiology* 4th ed. Current Biology, Garland, Churchill Livingstone, London, New York 1999; 1 – 31.

55. **Janeway CA, Travers P, Walport M, Capra JD. Manipulation of the Immune Response. In: Janeway CA, Travers P, Walport M, Capra JD eds. Immunobiology 4th ed. Current Biology, Garland, Churchill Livingstone, London, New York 1999; 537 – 78.**
56. **Janeway CA, Travers P, Walport M, Capra JD. T-cell Mediated immunology. In: Janeway CA, Travers P, Walport M, Capra JD eds. Immunobiology 4th ed. Current Biology, Garland, Churchill Livingstone, London, New York 1999; 263 – 305.**
57. **Janeway CD, Moll H: Duirensis in children with nephrosis. Trans Assoc Am physi 1948; 61: 108.**
58. **John B. T lymphocyte and NKcs In Stites PD, Stobo JD, Wells JV, eds. Basic and Clinical Immunologic 8th ed. Norwalk, Appleton and Lange 1994: 94 – 101.**
59. **Joos T, Oppenheim MD, Francis W; Cytokines In Stites PD, Stobo D, Wells JV, eds. Basic and Clinical Immunology 8th ed Norwalk, Appleton and Lange 1994: 105 – 113.**
60. **Joseph A, Kadlec JV: Cytokines and the immune response. Pediatr Clin North Am 1994; 41(4): 597 – 621.**
61. **Juluis M, Marown CR: Distinct roles for CD4 and CD8 as a co-receptor in Ag receptor signaling. Immunol Today 1993; 14: 177.**
62. **Kahout EC, Edwards GA, Hill LL: Focal glomerulosclerosis: Extent of involvement related to steroid resistance. Am J Clin Pathol 1981; 66: 545.**
63. **Kanffman JF, Auffray C, Korman AJ: The class II of the human and murine MHC. Cell 1984; 36: 1.**

- 64- **Kanwar YS**: Biology of disease: Biophysiology of glomerular filtration and proteinuria. *Lab Invest* 1984; 51: 7.
- 65- **Kaysen GA**: Albumin metabolism in the NS. The effect of dietary protein intake. *Am J Kidney Dis* 1988; 12: 461.
- 66- **Kerjaschki DK, Sharkey DJ**: Identification and characterization of podocalyxin. The major sialoprotein of the renal glomerular epithelial cell. *J cell Biol* 1984; 98: 1591.
- 67- **Kleinknecht C, Habib R**: Membranous glomerulonephritis. In: Holliday MA, Barratt TM, eds. *Pediatric Nephrology* 2nd ed. Baltimore: Williams and Wilkins 1987; 462: 9.
- 68- **Koizumi H, Liu CC**: Expression of perforin and serine esterases by human Tcs. *J Exp Med* 1991; 173: 499.
- 69- **Konrad M, Mytilineos J, Ruder H**: HLA DR7: Predicts the response to alkylating agents in steroid sensitive NS. *Pediatr Nephrol* 1997; 11 (1) : 16-9.
- 70- **Krensky AM, Ingelfinger JR**: Pediatrics in childhood NS. *Am J Dis Child* 1982; 36: 732.
- 71- **Krishna GG, Donavitch GM**: Effects of water immersion on renal function in the NS. *Kidney Int* 1982; 21: 395.
- 72- **Lakeda Y**: Evaluation of bone mineral turnover in children with NS. The implication of original disease and the effects of corticosteroids on bone mineral metabolism 1993; 35(6): 705 – 13.
- 73- **Lanbert RW, Deores PB, Fu IY**: Urinary and plasma vitamin D3 metabolism in the NS. *Metab Bone Dis Rel Res* 1982; 4: 7.

- 74- **Largue G:** Lymphokines and NS. *Lancet* 1975; 1:271.
- 75- **Lejani A:** Relapsing NS. *Nephron* 1987; 45: 81 – 5.
- 76- **Levin M, Gascoine P, Turner MW:** A highly cationic protein in plasma and urine of children with steroid responsive NS. *Kidney Int* 1989; 36 : 867.
- 77- **Levin M, Gascoine P:** A highly cationic protein in plasma and urine of children with steroid responsive NS. *Kidney Int* 1989; 36: 867.
- 78- **Liach F:** Hypercoagulability, renal vein thrombosis and other thromboembolic complication of NS. *Kidney Int* 1985; 28: 429.
- 79- **Lin JT, Lin Cy, Hyarug FY:** A clinicopathological study of INS in children. *Nippon Jinzo Gakkar Shi* 1995; 37(8): 442.
- 80- **Lowenstein J, Schacht RG, Baldwin DS:** Renal failure in MCNS. *Am J Med* 1981; 70: 227.
- 81- **Maddon PJ, Littinan DR:** The isolation and nucleotide sequence of C DNA encoding the T cell surface protein T4: A new member of the Ig gene family. *Cell* 1985; 42: 93.
- 82- **Mandreoli M, Betrandi E, Casadei MM, Mancini R, Zuccheli A, Zuccheli P.** Lymphocyte release of soluble IL-2 receptors in patients with minimal change nephropathy. *Clin Nephrol* 1992; 37 (4): 177 – 82.
- 83- **Manna AL, Polito C:** Levamisole in children's INS. *Child Nephrol Urol.* 1988; 9: 200 – 2.

- 84-**Markeinson DS, Levin D, Schacht R:** Primary peritonitis as a presenting feature of NS: a case report and review of the literature. *Pediatr Emerg Care* 1999; 15(6): 407 – 9.
- 85-**Martin A, Chester M. The nephrotic syndrome. In: Chester M, Edelman JR, eds. Pediatric kidney Disease. 2nd ed. Boston, Toronto: Little, Brown and Company 1992: 1247-1290.**
- 86-**Matsumoto K, Osakabe K, Harada M, Hatono M.** Impaired cell mediated immunity in lipoid nephrosis. *Nephron* 1981; 29: 190 – 4.
- 87-**McEnery PT, McAdams AJ, West CD:** Membranoproliferative glomerulonephritis improved survival with alternative day prednisone therapy. *Clin Nephrol* 1980; 13: 117 – 24.
- 88-**McEnery PT, Strife CF.** Nephrotic syndrome in childhood; management and treatment in patients with MCNS, mesangial proliferation or focal glomerulosclerosis. *Pediatr Clin North Am* 1982; 89: 872-94.
- 89-**Mcvicar ME, Chandra M, Magouleff:** Splenic hypofunction in the NS of childhood. *Am J Kid Dis* 1986; 7: 395.
- 90-**Meadow SR:** Steroid responsive NS and allergy: Immunological studies. *Arch Dis Child* 1984; 56: 509.
- 91-**Mehls O, Andrassy K:** Haemostasis and thromboembolism in children with NS. *J Pediatr* 1987; 110 : 862.
- 92-**Mehta KP, Ali U:** Immune regulatory treatment for MCNS. *Arch Dis Child* 1986; 61: 135 – 8.

- 93- **Mehta M, Bagga A, Pande:** Behavior problems in NS. *Indian Pediatr* 1995; 32(12): 1281 – 6.
- 94- **Meuleman J and Katz P:** The immunologic effect, kinetics and use of glucocorticoid. *Med Clin N Am* 1985; 69: 805.
- 95- **Miller K, Dresner IG, Micheal AF:** Localization of platelet Ag in human Kidney disease. *Kidney Int* 1980; 18: 972 – 9.
- 96- **Minchin MA:** Lymphocyte blastogenesis in NS: *Clin Exp Immunol* 1980; 42: 241.
- 97- **Monaco JJ:** A molecular model of MHC class I restricted Ag processing. *Immunol Today* 1992; 13: 173.
- 98- **Moore DH, Schackelford PG, Robson AM:** Recurrent pneumococcal sepsis and defective opsonization after pneumococcal capsular polysaccharide vaccine in a child with NS. *J Pediatr* 1980; 96: 882.
- 99- **More IAR. Glomerulonephritis. In: Anderson JR. eds.** Muir's text book of pathology, 12th ed. London: Edward Arnold LTd, 1987: 15 – 39.
- 100- **Nagata K, Platt JL:** International and glomerular immune cell population in INS. *Kidney Int* 1984; 25: 88.
- 101- **Neefjes JJ, Ploegh HL:** Intercellular transport of MHC Class II molecules. *Immunol Today* 1992; 3: 179.
- 102- **Nelson DL, Rubin LA, Kurman CC.** An analysis of the cellular requirements for the production of soluble IL-2R in vitro. *J Clin Immunol* 1986; 6: 1 – 7.

- 103- **Neuhaus Tj, Shah V, Callard RE, Baratt TM.** T-lymphocyte activation in steroid-sensitive nephrotic syndrome in childhood. *Nephrol Dial Transplant* 1995; 10 (8): 1348 – 52.
- 104- **Niandet P, Habib R:** Treatment of severe childhood nephrosis. *Adv Nephrol* 1988; 17: 151 – 72.
- 105- **Ohno I, Gomi H, Matsuda H, Nakano H, Matsumoto H, Kodama K, Iohimoto F, Sakai O.** Soluble IL-2 receptor in patients with primary nephrotic syndrome. *Nippon Jurzo Gakkai Shi* 1991; 33 (5): 483 – 9.
- 106- **Oppenheim JJ, Ruscetti FW, Faltynek C.** Cytokines. In: Stites DP, Stobo JD, Wells JV eds. *Basic & Clinical Immunology* 8th ed. Appleton & Lange, Norwalk, Connecticut 1994; 105 – 23.
- 107- **Parnes JR:** Molecular biology and function of CD4, CD8. *Adv Immunol* 1989; 44: 265.
- 108- **Perico N, Delaini F, Lupini L:** Blunted excretory response to atrial natriuretic peptide in experimental nephrosis. *Kid Int* 1989; 36: 57.
- 109- **Podack ER, Kupfer A:** T cell effector functions mechanism for delivery of cytotoxic and help. *Ann Rev Cell Biol* 1991; 7: 479.
- 110- **Primack WA, Rosel M:** Failure of pneumococcal vaccine to prevent strep pneumoniae sepsis in nephrotic children. *Lancet*, 1979; 2: 1192.
- 111- **Reinherz EL, Morimoto:** Regulation of B cell Ig secretion by functional subsets of T cells in man. *Eur J Immunol* 1980; 10: 570 – 72.

- 112- **Robson AM, Cole BR, Kienstra RA:** Severe glomerulonephritis complicated by coagulopathy. Treatment with anticoagulant and immune suppressive drugs. *J Pediatr* 1977; 90: 881 – 92.
- 113- **Rosen S:** Glomerular disease. *Human Pathol* 1981; 12: 964.
- 114- **Rubin LA, Kurman CC, Fritz ME:** Soluble IL-2R are released from activated lymphoid cells in vitro. *J Immunol* 1985; 135: 2172 – 3177.
- 115- **Ruscetti FW:** IL-2 in immunephysiology Oppenheim J, Shevach eds. Oxford Uni press 1990.
- 116- **Sagripanti A, Cirpisti A, Fredeghini M:** Molecular marker of hemostasis activation in nephrotic syndrome. *Nephron* 1989; 51: 25 – 8.
- 117- **Sato KA, Gray RW, Lemmann J:** Urinary excretion of 25,OH vitamin D in health and the NS. *J Lab Clin Med* 1982; 99: 325.
- 118- **Saxena S, Mittal A, Andal A.** Pattern of interleukins in minimal – change nephrotic syndrome of childhood. *Nephron* 1993; 65: 56 – 61.
- 119- **Schaller JG.** Allergic disorders. In Beherman RE, Kliegman RM, Nelson WE, Vanghan III VC eds, *Nelson Text Book of Pediatrics*. 14th ed, WB Saunders Company Philadelphia, London, Toronto 1992: 851-3.
- 120- **Schnaper HW, Aune TM:** Identification of lymphokine soluble immune response suppressor in urine of NS children. *J Clin Invest* 1985; 76: 341.

- 121- **Schnaper HW, Aune TM:** Steroid sensitive mechanism of soluble immune response suppressor production in steroid sensitive NS. *J Clin Invest* 1987; 79 : 251.
- 122- **Schnaper HW, Wade AL:** Characterization of a regulatory system for soluble immune response suppressor production in steroid sensitive NS. *Kidney Int* 1989; 35: 373.
- 123- **Schrier RW:** Pathogenesis of sodium and water retention in NS, cirrhosis and pregnancy. *N Engl J Med* 1988; 319: 1065 – 1127.
- 124- **Schulman SL, Kaiser BA:** Predicting the response to cytotoxic therapy for childhood NS: Superiority of response to corticosteroid therapy over histopathologic pattern. *J Pediatr* 1988; 113: 996 – 100.
- 125- **Shalhoub RJ:** Pathogenesis of lipoid nephrosis: A disorder of T-cell function. *Lancet* 1974; 2: 556.
- 126- **Spika JS, Halsey NA:** Decline of vaccine induced antipneumococcal antibody with NS. *Am J Kidney Dis* 1988; 7: 466.
- 127- **Stachowski J, Barth C, Michalkiewicz J, Krynicki T, Jarmolinski T, Runowski D, Lewandowska-Stachowiak M, Zaniew M, Warzywoda A, Bortkiewicz E, Dobosz M, Maciejewski J, Baldamus CA.** Th1/Th2 balance and CD45 – positive T-cell subsets in primary nephrotic syndrome. *Pediatr Nephrol* 2000; 14 (8-9): 772 – 5.
- 128- **Svetlov SI, Moskaleva ES, Pinels VG:** Decreased intra platelet Ca^{2+} release and ATP secretion in pediatric NS. *Pediatr Nephrol* 1999; 13(3): 205 – 8.

- 129- **Tain YL, Lin G, Cher TW:** Microbiological spectrum of septicemia and peritonitis in nephrotic children. *Pediatr Nephrol* 1999; 13(9): 835-7.
- 130- **Tejani A, Bitt K:** Cyclosporin A and induced remission of relapsing NS. *Kidney Int* 1988; 33: 729.
- 131- **The international study of kidney Disease in Children:** MCNS in children: Deaths during the 1st 5 – 15 year's observation. *Pediatrics* 1984; 73: 497.
- 132- **Topaloglu R, Soatci U, Arikan M, Canpinar H, Bakkaloglu A, Kansu E.** T-cell subsets, interleukin-2 receptor expression and production of interleukin-2 in minimal change nephrotic syndrome. *Pediatr Nephrol* 1994; 8 (6): 649 – 52.
- 133- **Trinchieri G:** IL-12 and its role in the generation of THI cells. *Immunol Today* 1993; 14: 335.
- 134- **Tristran G, Parslow IG:** Lymphocytes and lymphoid tissues. In: Stites PD, Stabo JD, Wells JV, eds, *Basic and Clinical immunology*. 8th ed Norwalk, Appleton and Lange, Connecticut 1994: 22 – 31.
- 135- **Tune BM, Kirpeker R, Sibley RK:** Intravenous methyl prednisone and oral alkylating agent therapy of prednisone resistant pediatric FSGS: a long term follow up. *Clin Nephrol* 1995; 43(2): 84 – 8.
- 136- **Ullnon K:** Transmission of signals from T lymphocyte Ag receptor to the gene responsible for T cell proliferation and immune function. *Ann Rev Immunol* 1990; 8: 421.

- 137- **Vande W, Walle JG, Doncker A, Wolche RA:** Pathophysiology of edema formation in children with NS. *J Am Soc Nephrol*, 1999; 10(2): 323 – 31.
- 138- **Varley H, Gowenlock AH, Bell M.** Practical Clinical Biochemistry. Volume I General Topics and Commoner Tests 5th ed reset. London: Williams Heinmann Medical Books LTd 1980: 495: 1131.
- 139- **Vermlyen CG, Levin M:** Decreased sensitivity to heparin in vitro in steroid-responsive NS. *Kidney Int* 1987; 31: 1396.
- 140- **Vernier RL, Klein DJ, Sisson SP:** Hepatan sulphate rich an tonic sites in the human glomerular basement membrane. *N Engl J Med*; 1983; 309: 100.
- 141- **Vernier RL:** Primary NS. In Holliday MA, Barratt TM, eds. *Pediatric nephrology*, 2nd ed Baltimore: Williams and Wilkins 1987; 445 – 56.
- 142- **Waldman TR:** The mulisubunit IL-2R. *Ann Rev Biochem* 1989; 58: 875.
- 143- **Waller KV, Ward KM, Mahan JD:** Current concepts in proteinuria. *Clin Chem* 1989; 35: 755.
- 144- **Wauhaus TJ, Wadhua M, Callard R, Boratt TM.** Increased IL-2, IL-4 and interferon-gamma (IFN- γ) in steroid-sensitive nephrotic syndrome. *Clin Exp Immunol* 1995; 100 (3): 475 – 9.
- 6 145- **Weiss EH, Galden L:** Organization and evaluation of the class I gene family with MHC of the C57 BL/10 mouse. *Nature* 1984; 310: 650.

- 146-**West CD, McAdams AJ:** Membranoproliferative glomerulonephritis. In: Holliday MA, Barratz TM, eds. Pediatric nephrology 2nd Baltimore: Williams and Wilkins 1987; 420 – 30.
- 147-**Wheeler DC, Varghese Z, Moorhead JF:** Hyperlipidemia in NS. Am J Nephrol 1989; 9: 78.
- 148-**Whiteside C, Prutis:** Glomerular epithelial detachment correlates with proteinuria in adriamycin and puromycin nephrosis. Lab Invest 1989; 1: 215.
- 149-**Wilkes JS, Nelson JD, Worthen HG:** Response to pneumococcal vaccination in children with NS. Am J Kidney Dis 1982; 2: 43.
- 150-**Winkelestein A.** Immunosuppressive therapy: In Stites DP, Stobo JB, Wells JV, eds, Basic and Clinical immunologic 765 – 9.
- 151-**Winkelstein A. Immuosuppressive therapy. In: Stites DP, Stobo JD, Wells JV eds.** Basic & Clinical Immunology 8th ed. Appleton & Lange, Norwalk, Connecticut 1994; 765 – 80.
- 152-**Yermiah T, Shalev H, Landan B:** Protein C and protein S in pediatric nephrotic patients: Sangrec Barc. 1996; 41(2): 155 – 7.
- 153-**Zhang DY, Ye RG, Li YJ.** Changes in soluble interleukin-2 receptor and its significance in nephrotic syndrome. Chung Hua Nei Ko Tsa Chih 1994; 33 (5): 309 – 12.
- 154-**Zilleruelo G, Hsia SL:** Persistence of serum lipid abnormalities in children with INS. J Pediatr 1984; 104: 61.
- 155-**Zilleruelo G, Hsia SL:** Persistence of serum lipid abnormalities in children with INS. J Pediatr 1984; 104: 61.

- 156- **Zweiman B:** Corticosteroid effects on circulating lymphocyte subset levels in normal human. *J Clin Immunol* 1984; 4: 151.